Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. (Q36932510)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

title

Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Steven G Waguespack

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Montserrat Ayala-Ramirez

1

object named as

Montserrat Ayala-Ramirez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Cecile N Chougnet

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

J Lynn Palmer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Sophie Leboulleux

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Maria E Cabanillas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Caroline Caramella

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Pete Anderson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Abir Al Ghuzlan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Desirée Deandreis

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Eric Baudin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

Camilo Jimenez

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

10 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

The Journal of Clinical Endocrinology and Metabolism

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

4040-4050

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma.

12 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Metastatic pheochromocytoma and paraganglioma: focus on therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Update on systemic therapies of metastatic renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Sunitinib: from rational design to clinical efficacy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Therapeutic targets: MTOR and related pathways

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Mutations associated with succinate dehydrogenase D-related malignant paragangliomas

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Genetic testing in pheochromocytoma or functional paraganglioma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683800

VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22965939

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22965939

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22965939

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1210/JC.2012-2356

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22965939 AND SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

22965939

1 reference